Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what ...

Investors' focus will likely be on GILD's HIV franchise performance and oncology sales when the company reports ...

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19-directed CAR-T therapy with positive readouts in the most cancer types. | With another trial win, Bristol Myers Squibb is ...

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

Zacks.com announces the list of stocks and ETFs featured in the Analyst Blog. Every day the Zacks Equity Research ana ...

This was the stock's second consecutive day of losses.

Wall Street analysts expect Gilead Sciences (GILD) to post quarterly earnings of $1.66 per share in its upcoming report, which indicates a year-over-year decline of 3.5%. Revenues are expected to be ...

Gilead Sciences Inc. hit a new 52-week high, surpassing its previous peak of $99.45, which the company achieved on February ...

Gilead Sciences Inc. must face a fired employee’s lawsuit alleging its response to a co-worker’s false sexual harassment ...

Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success.

In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...